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Abstract The pattern of the left ventricle (LV) has
important significance in adults with hypertension. The
aim of the present study was to analyze changes and
determinants of LV geometry after 1 year of antihyperten-
sive treatment in children with primary hypertension (PH)
in relation to metabolic abnormalities and anthropometrical
parameters. In 86 children (14.1±2.4 years) with newly
diagnosed PH, LV geometry and biochemical parameters
before and after 12 months of standard antihypertensive
therapy were assessed. At baseline, normal LV geometry
(NG) was found in 42 (48.9%), concentric remodeling (CR)
in 4 (4.6%), concentric hypertrophy (CH) in 8 (9.3%), and
eccentric hypertrophy (EH) in 32 (37.2%) patients. The
prevalence of NG in patients with severe hypertension was
significantly lower than in patients with ambulatory
hypertension. There were no differences in dipping status
in relation to LV geometry. Patients with CH and EH were
more viscerally obese than patients with NG. Patients with
CH had higher diastolic blood pressure in comparison with
EH patients (p<0.05). The main predictor of relative wall
thickness (RWT) was the triglycerides to high density
lipoprotein cholesterol (TG/HDL) ratio (R
2=0.319, β=
0.246, p=0.004). Patients received 12 months of antihy-
pertensive treatment, either lifestyle modification only (n=
37) or lifestyle modification plus antihypertensive medi-
cations (n=49) if severe ambulatory hypertension or target
organ damage were present. After 12 months of treatment
the prevalence of EH (37.2% vs 18.6%, p=0.003)
decreased but prevalence of CH did not change. Patients
in whom RWT decreased also decreased waist circumfer-
ence and TG/HDL; the main predictor of RWT decrease
was a decrease of the TG/HDL ratio (β=0.496, R
2=0.329,
p=0.002). In adolescents with PH, LV geometry is related
to central obesity and insulin resistance. Decrease of
abdominal obesity and insulin resistance are the most
important predictors of normalization of LV geometry,
however CH has lower potential to normalize LV geometry.
Keywords Primary hypertension.Left ventricular
hypertrophy.Left ventricular remodeling.Antihypertensive
treatment.Children
Introduction
Subclinical target organ damage (TOD) is present in 30–
40% of children with primary hypertension (PH) at the
diagnosis of elevated blood pressure (BP) [1–5]a n d
correlates with metabolic abnormalities, central obesity,
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has clinical importance because of increased cardiovascular
morbidity in adults with TOD [9, 10]. Left ventricular
hypertrophy (LVH) is the most clinically useful marker of
TOD. The left ventricle (LV) may adapt to hypertension by
developing concentric or eccentric LVH (CH, EH respec-
tively), concentric left ventricular remodeling (CR), or by
retaining normal LV geometry (NG). Each geometric
pattern is associated with a distinct combination of pressure
and volume stimuli, contractile and diastolic efficiency
(reduced in those with CR or CH) and prognosis (worst
with CH and best with NG) [11, 12]. The relation between
LV remodeling and metabolic abnormalities in children
with PH has not been fully explored [13].
To date, there are only limited data on the effectiveness
of antihypertensive treatment in adolescents with PH and
even fewer data exist on the regression of LVH and changes
in geometric abnormalities [14–16]. Previously, we found
that the main determinant of LVH regression was a decrease
in visceral obesity [16]. The aim of the present study was to
analyze changes and determinants of LV geometry after
1 year of antihypertensive treatment in the same group of
children with PH in relation to metabolic abnormalities and
anthropometrical parameters.
Patients and methods
The study adhered to the principles of the Declaration of
Helsinki and was approved by the local Ethics Committee.
All parents and children who were literate and able to
understand age-based patient information provided written
informed consent.
Patients
The study group has already been described [16]. In short,
86 children (20 girls) with untreated PH, mean age 14.1
(range: 5–17 years) and who completed all investigative
procedures, were enrolled onto the study. PH was diag-
nosed after a thorough clinical and laboratory diagnostic
work-up, according to recently published recommendations
[17, 18]. The exclusion criteria were: diagnosis of secondary
hypertension, previous use of antihypertensive drugs,
presence of any significant chronic disease (except for
PH), any acute disease, including infections, in the
6 weeks preceding enrollment, and incomplete data.
Normal office blood pressure values were taken from the
Updated 4th Task Force Report [17]. In all patients the
diagnosis was confirmed by 24-h ambulatory blood
pressure monitoring (ABPM). ABPM was performed at
the initial visit and after 12 months. Recordings lasting at
least 20 h with at least 80% of records considered valid.
Blood pressure values were calculated from the ABPM data
as the mean 24-h systolic (SBP) and diastolic (DBP) blood
pressure and presented as absolute values and as systolic
and diastolic blood pressure indices (SBPI and DBPI
respectively) calculated as the ratio of SBP or DBP to the
95th percentile for age and gender based on the pediatric
ABPM reference data [19]. We used a recently published
classification system based on ABPM to classify patients as
having normal blood pressure, ambulatory hypertension, or
severe ambulatory hypertension [20].
Methods
All patients underwent the following assessments: anthro-
pometrical measurements including body mass index
(BMI), waist circumference (WC), waist-to-hip ratio
(WHR) andwaist-to-heightratio (WHTR),echocardiography,
urinary albumin excretion, serum glucose and insulin, blood
lipids, serum homocysteine, serum uric acid and C-reactive
protein (hsCRP), and serum asymmetric dimethylarginine
(ADMA) concentrations. In addition, in all patients oxidative
stress markers, i.e., thiobarbituric acid reactive substances
(TBARS), oxidized LDL-cholesterol (oxyLDL) concentra-
tions, and anti-oxidative defense (reduced glutathione con-
centration [GSH], glutathione peroxidase activity [GPX])
were measured. Obesity and overweight was diagnosed
according to International Obesity Task Force recommenda-
tions[21]. Because some of our patients were below 10 years
of age, metabolic syndrome was diagnosed as described
previously, and when at least three criteria were present
(BMI≥ 95th percentile for age and gender, arterial
hypertension, serum triglycerides>110 mg/dl, fasting plasma
glucose>100 mg/dl or>140 mg/dl at 2 h of oral glucose
tolerance test and HDL cholesterol<40 mg/dl) [6].
Echocardiography
All echocardiography (ECHO) examinations were performed
by one examinerwho knewthe clinicaldiagnosis, but was not
aware of the severity of PH or effectiveness of treatment.
ECHO measurements were performed according to the
American Society of Echocardiography guidelines [22, 23].
To standardize left ventricular mass to height, the left
ventricular mass index (LVMi) was calculated according to
the deSimone formula [24]. LVH was defined as an LVMi
value above 95th percentile for age and gender based on the
pediatric LVMi reference data of Khoury’s[ 25]. Relative
wall thickness (RWT) was measured at end diastole as the
ratio of posterior wall thickness plus interventricular septum
thickness over LV internal dimension. A RWT of 0.41,
which represents the 95th percentile for RWT for normal
children and adolescents, and the 95th percentile of LVMi
for age and gender for normal children and adolescents were
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Normal geometry was defined as RWT <0.41 and LVMi<
value of 95th percentile, RWT <0.41 and LVMi>value of
95thpercentileofLVMidefinedEH,RWT>0.41andLVMi>
valueof95thpercentileofLVMidefinedCH,andRWT>0.41
and LVMi<95th percentile of LVMi defined CR.
Laboratory investigations
Blood samples were taken after 12 h of fasting and were
immediately sent to the laboratory. Plasma glucose levels
were measured using a Dimension analyzer. Plasma insulin
concentrations and glycated hemoglobin (HbA1C) were
measured by radioimmunoassay. Oral glucose tolerance test
was carried out in all patients after oral ingestion of 1 g/kg
body weight (maximum 75 g) of glucose. Insulin resistance
was expressed as homeostasis model assessment for insulin
resistance (HOMA-IR) and as a triglycerides to high
density lipoprotein cholesterol (TG/HDL) ratio [27, 28].
The hsCRP concentration was assayed using a highly-
sensitive immunoturbidimetry kit (Orion Diagnostica).
Plasma lipid peroxides were determined with the spectroflu-
orometric method of Yagi and expressed as thiobarbiturate
reactive substance (nmol/ml). Glutathione and glutathione
peroxidase activity were used as indicators of antioxidant
status and were measured spectrophotometrically in erythro-
cytes (GSH-420(Oxis) and GPx-340(Oxis)). OxyLDL and
asymmetric dimethyloarginine (ADMA) concentrations were
measured by ELISA using a commercially available kit.
Urinaryalbuminexcretionin24-hsampleswasdeterminedby
theimmunonephelometricmethod.Thelaboratoryprocedures
have been described in detail in a previous study [6].
Antihypertensive treatment
The principles of treatment were the same as previously
described [16]. In short, pharmacological treatment was
started in patients who had significant TOD and/or severe
ambulatory hypertension. BP was checked at 3 and
6 months during ambulatory visits. If after 3 or 6 months
office BP was still within the hypertensive range, ABPM
was carried out. In patients who still had ambulatory or
severe ambulatory hypertension, pharmacotherapy was
started or another drug was given. Finally, in all patients
ABPM was done after 12 months of treatment. Patients
who after 12 months of treatment lowered ABPM to below
the 95th percentile were treated as responders and those
who did not, as non-responders. Drug therapy was based on
an angiotensin converting enzyme inhibitor (ACEi), enalapril
(0.2–0.3 mg/kg/day bid). Patients who had asthma or did not
tolerate ACEi were prescribed an angiotensin 2 receptor type
1 blocker (ARB), losartan (0.7–1 mg/kg/day in one or two
daily doses). If patients were unable to buy the prescribed
medications (enalapril or losartan), amlodipine was used at a
s t a n d a r dd o s eo f5m go n c ed a i l y .D e t a i l e dd e s c r i p t i o n s
of the principles of treatment are shown in the Electronic
Supplementary Material (ESM).
Statistical analysis
Because the analyzed groups included subjects of different
ages and genders, BMI and WC values were expressed both
as absolute values and as SDS for age and gender. LVM
values in grams were standardized to height in meters
2.7.
The change of measured parameters was expressed as a
delta value (Δ), i.e., the difference between measurement at
12 months and at the start of treatment. Homogeneity of
variance was checked with the Levene test. Continuous
variables with a normal distribution were compared using
Student’s t test for independent variables. Continuous
values with non-normal distribution were compared using
the Mann–Whitney U test. Comparison between groups
was evaluated with ANOVA test using Bonferroni correction.
Measurements taken at the start and after 12 months of
treatment were compared using the Wilcoxon test.
Dichotomous variables were compared using the Chi-squared
test and change in prevalence during treatment was analyzed
with the McNemar test. Correlation analysis was carried out
with the Spearman test. RWTand Δ for RWTwere dependent
variables. Variables with significant correlation or that differed
between groups of patients in whom LV geometry was
normalized ornot, werethen included in thestep-wise multiple
regression analysis. A p value less than 0.05 was regarded as
statistically significant. A p value ranging between 0.05 and
0.1 was regarded as a statistical tendency.
Results
Descriptive demographic, clinical, and laboratory data
obtained at the start and after 12 months of treatment are
summarized in Table S1 (ESM).
First evaluation
According to the International Obesity Task Force criteria,
67%ofpatientswereobeseoroverweight(58patients).Forty-
two (48.9%) patients had NG, 4 (4.6%) had CR, 8 (9.3%) had
CH, and 32 (37.2%) EH. Patients with CH and EH were more
viscerallyobesethanpatientswithNG(Table1). Patients with
CH in comparison with patients with EH had greater DBP
and a tendency towards a greater birth weight (p=0.1). EH
was more prevalent among obese than non-obese patients.
Patients with severe ambulatory hypertension (n=36) had
greater LVMi than patients with ambulatory hypertension
(n=50; 42.3 ±12.1 g/m
2.7 vs 35.7 ±8.7 g/m
2.7, p<0.01) and
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(58% vs 38%, Chi-squared=3.48, p=0.06). The preva-
lence of NG in patients with severe ambulatory hyperten-
sion was significantly lower (13 patients, 36.1% vs 29
patients, 58%, p=0.04, Chi-squared=4.01). Patients with
ambulatory and severe ambulatory hypertension did not
differ in terms of RWT. There were no differences
regarding dipping profiles among patients with different
patterns of LV geometry. RWT correlated with WHR (p<
0.05, r=0.25), TG/HDL ratio (p<0.05, r=0.29), and
TBARS concentration (p<0.01, r=0.35). The main pre-
dictor of RWT was the TG/HDL ratio (R
2=0.319, β=
0.246, p=0.0004), and the main predictor of LVMi was
WC (R
2=0.279, β=0.561, p=0.008).
Second evaluation after 12 months
Throughout the study, 37 (43%) patients were prescribed
only non-pharmacological therapy, including dietary advice
and increased physical activity. Thirty-four (39.5%) patients
received one antihypertensive medication, 9 patients
(10.5%) received two drugs (ACEi or ARB plus amlodipine),
and 6 (7%) received three drugs (ACEi or ARB plus
amlodipine and metoprolol). As reported earlier, overall after
12 months, BP normalized below the 90th percentile in 54
(62.8%) patients, 10 patients were in the pre-hypertensive
range (11.6%), 21 (24.4%) patients had ambulatory
hypertension, and 1 (1.2%) had severe ambulatory
hypertension, but the decrease in hypertension severity
was significant [16]. The prevalence of LVH decreased
from 40 (46.5%) to 24 (27.9%; p=0.003; Chi-squared
=8.65). RWT decreased in 41 patients and LVMi in 58
patients. The number of patients with NG increased (to 56
patients), and that of patients with EH decreased (to 16
patients) significantly (Table S1 ESM). Of 42 patients who
had NG at first examination, 34 still had NG after
12 months. The 8 patients who developed abnormal LV
g e o m e t r y( 3C R ,2C H ,a n d3E H )h a das i g n i f i c a n t l y
Table 1 Descriptive demographic, clinical and laboratory data according to the left ventricular geometric pattern at the first evaluation. Only
significant differences (p<0.05) or statistical tendencies (p in the range 0.05–0.1) are shown
NG1 42 (48.9%) CR1 4 (4.6%) CH1 8 (9.3%) EH1 32 (37.2%) p
Birth weight (g) 3,400 (1,410–4,100) 3,495 (3,130–3,850) 3875 (2850–5300) 3300 (2100–5250) NG1 vs CH1 <0.01
CH1 vs EH1<0.11
BMI (kg/m
2) 23.9 (15.2–39.7) 20.7 (18.9–22.8) 25.9 (21.9–27.9) 27.1 (19.8–39.1) NG1, CR1 vs EH1 <0.05
WC (cm) 78 (53–98.5) 75 (67–80) 87 (78–96) 93 (66–111) NG1 vs CH1, EH1 <0.05,
CR1 vs CH1, EH1<0.05
WHR 0.81 (0.72–0.91) 0.89 (0.78–0.97) 0.87 (0.78–1.03) 0.88 (0.73–1.03) NG1 vs EH1<0.01,
NG1 vs CH1=0.07
Patients with ambulatory
hypertension (%)
29 (69%) 2 (50%) 4 (50%) 15 (46.8%) NG1 vs EH10.05,
Chi-squared=3.70
Patients with severe
ambulatory
hypertension
13 (31%) 2 (50%) 4 (50%) 17 (53.1%) NG1 vs EH10.05,
Chi-squared=3.70
Total cholesterol (mg/dl) 178 (100–290) 192 (181–243) 177 (130–205) 168 (94–236) CR1 vs EH1 <0.05
HDL (mg/dl) 44 (25–58) 49 (46–50) 44 (22–66) 42 (29–61) CR1 vs EH1<0.05
HbA1C (%) 5.4 (4.5– 6.7) 4.9 (4.2–5.0) 5.0 (4.4–5.4) 5.3 (4.1–6.8) CR1 vs NG10.05,
vs EH10.06
Insulin[0] (mU/ml) 13 (5.6–31 ) 13.5 (5–16) 11.7 (9.3–39) 13.6 (7.5–48) CH1 vs CR10.10,
CH1 vs EH10.11
Uric acid (mg/dl) 5.4 (2.7–8.6) 5 (4.2–5.6) 5.6 (3.2 –7.5) 5.6 (3.2–8.3) ns
GPX (U/g Hb) 31.2 (26.1–39.9) 30.2 (25.4–31.6) 32.6 (29.1–38.7) 31.8 (26.2–38.1) CR1 vs CH1 <0.05,
CR1 vs EH10.06
Thiobarbiturate reactive
substance (μmol/l)
0.24 (0.16–1.25) 0.42 (0.34–0.62) 0.30 (0.14–1.28) 0.32 (0.18–1.25) NG1 vs CR1, EH1<0.05
Overweight and obese
patients (%)
23 (54.8%) 1 (25%) 0 8 (100%) 26 (81.2%) NG1 vs EH10.01
Chi-squared=5.7, NG1
vs CH10.04, Chi-squared=
4.07, CR1 vs CH10.03,
Chi-squared=4.50
NG1, normal geometry at start of treatment; CR1, concentric remodeling at start of treatment; CH1, concentric hypertrophy at start of treatment;
EH1, eccentric hypertrophy at start of treatment; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; HbA1C,
glycated hemoglobin; glucose[0], fasting glucose concentration; GPX, glutathione peroxidase activity
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lower HDL than patients who still had NG (Table 2). Of
32 patients with EH at first examination, after 12 months
16 patients still had abnormal LV geometry (1 CR, 4 CH,
11 EH) and 16 patients (50%) had NG—patients who
normalized LV geometry had a tendency toward a lower
visceral fat accumulation in comparison with patients who
still had LVH (Table 2). Three (75%) of the 4 patients with
CR normalized LV geometry after 12 months and 3
patients (37.5%) with CH at first examination also moved
to the NG group after 12 months.
Patients who still had CH had greater DBP (73 [68–93]
vs 68 [58–79] mmHg, p=0.03), DBPI (0.94 [0.88–1.22] vs
0.86 [0.01–1.02], p=0.02) and GPX (31.6 [30.8–32.7] vs
30.5 [29.9–34.5] U/gHb, p=0.04) in comparison with
patients who had EH. Similarly, patients who still had CH
or who developed abnormal geometry had greater insulin
concentrations during the oral glucose tolerance test and
greater HbA1C after 1 year (Table 2). The decrease in DBP,
DBPI, and TG/HDL ratio after 12 months in patients with
CH was significantly lower than in patients with EH and in
patients with NG. Also, the decrease in uric acid concen-
trations in patients with CH was lower than in patients with
EH (Table 3). In general, patients who had lowered RWT
decreased WC and the TG/HDL ratio to a significantly
greater extent than patients with an increase or stabilization
of RWT (Table 4). The prevalence of metabolic syndrome
decreased in the subgroup of patients who had decreased
RWT in comparison with the subgroup of patients with
progression/stabilization of RWT. Similarly, the prevalence
of metabolic syndrome decreased (8 vs 1 case) only in the
group of 58 patients who had decreased LVMi (p=0.02;
Chi-squared=5.14). On the contrary, the prevalence of
metabolic syndrome did not change among patients who
did not have a decrease in LVMi. The decrease in RWT
correlated with decreases in WC (r=0.25, p<0.05), TG/
HDL ratio (r=0.38, p<0.01), albuminuria (r=0.32, p<0.05),
as well as with values of the TG/HDL ratio (r=−0.26, p<
0.01), RWT (r=−0.64, p<0.001), and LVMi (r=−0.35, p<
0.001) at the first evaluation and thiobarbiturate reactive
substance concentration at the first and the second evaluation
(r=−0.22, p<0.05 and r=−0.21, p<0.05 respectively). The
main predictor of RWT decrease was a decrease in the
TG/HDL ratio (β=0.496, R
2=0.329, p=0.002).
Discussion
There are three main findings of our study. First, EH is the
most frequently found pattern of LV remodeling in
Table 2 Differences between patients with normal left ventricular geometry and patients who had abnormal left ventricular geometry after
12 months. p Values of statistical significance (<0.05) and tendency (0.05–0.1) are shown
First examination Second examination
NG Abnormal geometry p
NG—42 patients n 34 8 (3 CR, 2 CH, 3 EH)
BMI (kg/m
2) 23.3 (15.3–36.3) 27.4 (19.7–33.5) 0.003
BMI-SDS 0.93 (−0.93 –5.74) 2.36 8–0.46–5.26) 0.006
WC (cm) 78.5 (52–101) 89 (71.5–102) 0.02
WC-SDS 0.96 (−1.72–3.71) 1.91 (−0.66–4.94) 0.03
WHR 0.81 (0.68–0.97) 0.87 (0.70–0.91) 0.04
WHtR 0.46 (0.37–0.56) 0.53 (0.41–0.57) 0.006
Uric acid (mg/dl) 4.9 (3.0–7.7) 6.4 (3.9–6.7) 0.04
HDL (mg/dl) 47 (29–66) 37.5 (30–47) 0.01
HbA1C (%) 5.2 (4.7–9.8) 5.5 (5.4–7.5) 0.03
CR—4 patients n 4 1 (CR)
CH—8 patients n 3 5 (1 CR, 2 CH, 2 EH)
Insulin[120] (mU/ml) 28.9 (25–35) 47 (31.1–90) 0.05
Δ Insulin[120] (mU/ml) −19 (−48–(−0.1)) 24 (0–29.3) 0.02
EH—32 patients n 16 16 (1 CR, 4 CH, 11 EH)
GSH 780.7 (694.1–821.7) 758.5 (638.1–819.3) 0.09
Abbreviations: n, number of patients; NG, normal geometry of left ventricle; CR, concentric remodeling; CH, concentric hypertrophy; EH,
eccentric hypertrophy; BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; WHtR, waist to high ratio; HbA1C, glycated
hemoglobin concentration; insulin[120], insulin concentration after 120 min of oral glucose ingestion; HDL, high density lipoprotein cholesterol;
GSH, reduced glutathione; SDS, standard deviation score
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significance (<0.05) and tendency (0.05–0.1) are shown
NG2 CR2 CH2 EH2 p
Number of patients (%) 56 (65.1%) 6 (7%) 8 (9.3%) 16 (18.6%)
Δ BMI (kg/m
2) 0.49 (−8.54–3.48) 0.42 (−1.73–2.30) 0.55 (−1.97–7.69) 0.09 (−5.63–5.14) ns
Δ BMI-SDS 0.11 (−5.26–1.23) −0.16 (−0.52–0.72) −0.16 (−0.92–2.61) 0.13 (−1.76–1.60) ns
Δ WC (cm) 0.25 (−23.5–8.5) −0.75 (−7–3.5) −1.5 (−4.5–18.5) −2.5 (−17–4) NG2 vs EH20.02
Δ WC-SDS −0.13 (−4.04–0.99) −0.29 (−1.45–0.03) −0.39 (−0.98–1.97) −0.45 (−2.22–0.50) NG2 vs EH20.05
Δ WHR 0 (−0.01–0.09) −0.02 (−0.09–0.01) −0.01 (−0.09–0.09) −0.02 (−0.18–0.04) ns
Δ WHtR 0 (−0.14–0.05) −0.01 (−0.09–0.02) −0.01 (−0.06–0.09) −0.03 (−0.10–0.01) NG2 vs EH2 0.007
Δ SBP/24h (mmHg) −5( −33–20) −3( −18–12) −2( −13–7) −1( −19–4) ns
Δ SBPI/24h −0.05 (−0.29–0.27) −0.03 (−0.14–0.09) −0.02 (−0.16–0) −0.04 (−1.01–0.01) ns
Δ DBP/24h (mmHg) −2( −30–19) 1(−13–4) 5 (−15–23) −2( −13–4) CH2 vs NG2, EH2 <0.05,
CH2 vs CR20.10
Δ DBPI/24h −0.03 (−1.04–0.25) 0.01 (−0.16–0.05) 0.06 (−0.20–0.30) −0.03 (−0.77–0.13) CH2 vs NG2, EH2 <0.05,
CH2 vs CR20.15
Δ TG/HDL −0.11 (−5.77–2.63) −0.04 (−1.59–0.85) 0.94 (−0.77–4.41) −0.12 (−2.45–1.50) CH2 vs NG2, EH2 <0.05
Δ HOMA-IR −0.10 (−3.71–8.14) −0.70 (−2.23–0.69) 1.34 (−0.66–4.05) 0.01 (−1.47–0.59) CH2 vs CR2 <0.05,
CH2 vs NG20.1
Δ uric acid (mg/dl) −0.1 (−2.7–0.8) 0.2 (−0.5–1.6) 0.1 (−0.2–2) −0.7 (−2.4–2.7) EH2 vs. CH2, CR2 <0.05,
EH2 vs NG20.05,
ΔADMA −0.06 (−0.58–0.53) −0.11 (−0.33–0.07) 0.33 (0.08–0.91) −0.14 (−0.91–0.30) CH2 vs NG2, CR2<0.05,
CH2 vs EH20.08
NG2, normal geometry after 12 months of antihypertensive treatment; CR2, concentric remodeling after 12 months of antihypertensive treatment;
CH2, concentric hypertrophy after 12 months of antihypertensive treatment; EH2, eccentric hypertrophy after 12 months of antihypertensive
treatment; BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; WHtR, waist to high ratio; SBP/24h, mean systolic blood
pressure in 24-h ambulatory blood pressure monitoring; SBPI/24h, index of mean systolic blood pressure in 24-h ambulatory blood pressure
monitoring; DBP/24h, mean diastolic systolic blood pressure in 24-h ambulatory blood pressure monitoring; DBPI/24h, index of mean diastolic
systolic blood pressure in 24-h ambulatory blood pressure monitoring; TG/HDL, triglycerides to high-density lipoprotein cholesterol ratio;
HOMA-IR, homeostasis model assessment for insulin resistance; ADMA, serum asymmetric dimethyloarginine; SDS, standard deviation score
Table 4 Differences between patients with regression of relative wall thickness (RWT) and in whom RWT was stable or increased. p Values of
statistical significance (<0.05) and tendency (0.05–0.1) are shown
Decrease of RWT,
n=41
Increase or stabilization
of RWT, n=45
p
Δ WC (cm) −1.5 (−23.5–8.5) 0 (−8–18.5) 0.029
ΔTG/HDL −0.10 (−5.77–1.47) −0.07 (−1.59–4.41) 0.03
ΔLVMi (g/m
2.7) −7.4±7.3 0.5±6.6 <0.0001
Δ urinary albumin excretion (mg/24h) −3.4 (−269.4–52) −0.9 (−103.3–128) 0.1
RWT1 (mm) 0.38 (0.23–0.67) 0.32 (0.25–0.41) 0.0001
RWT2 (mm) 0.33 (0.21–0.46) 0.36 (0.29–0.49) <0.001
LVMi1 (g/m
2.7) 41.7±10.1 35.5±10.6 0.008
LVMi2 (g/m
2.7) 34.2±6.8 36.2±8.2 ns
Number of patients with metabolic syndrome
at start of treatment
7* 6 ns
Number of patients with metabolic syndrome
after 12 months of treatment
1* 5 ns
RWT, relative wall thickness (RWT1, at start of treatment; RWT2, after 12 months of treatment); n, number of patients; WC, waist circumference;
TG/HDL, triglycerides to high-density lipoprotein cholesterol ratio; LVMi, left ventricular mass index; LVMi1, at start of treatment; LVMi2, after
12 months of treatment
*p=0.04, Chi-squared=4.17
2206 Pediatr Nephrol (2011) 26:2201–2209adolescents with PH. Second, the main determinants of
pathological remodeling of the LV are visceral obesity and
metabolic abnormalities. Third, both LVH and EH can be
reversed and LV geometry can fully normalize; however,
CH has less potential to normalize LV geometry.
Daniels et al. already found that EH was the most
frequent pathological pattern of LV remodeling [1]. This
type of LV remodeling is typical for states of volume
overload or as a consequence of long-standing cardiac
disease and heart failure [10, 11]. However, EH is also
typical for obesity, and obesity is the dominant intermediate
phenotype of children with PH [6, 29]. EH was also found
to be the most prevalent form of LVH in other studies in
hypertensive adolescents and young adults with relatively
short durations of PH. In the Strong Heart Study, in which
as many as 65% of patients had a BMI above 30, EH was
present in 20% of patients aged 14–39 with PH, and CH
occurred in just a few of them [30]. Assessing both the
pharmacologically treated and untreated children as well as
children with PH and secondary hypertension, Hanevold
et al. found CH in as many as 16% of patients, while EH
occurred in 20% of children [3]. In contrast to our
findings, Richey et al., who studied LV geometry in a
group of children with PH at the time of diagnosis and
before the initiation of antihypertensive therapy, found
CH and EH with the same frequency (19.1%), and NG
in 51.5% of patients. They also observed that patients
with EH had a higher DBP compared with other groups
[31]. The differences between our results and those of Richey
et al. may be explained by racial differences. All our patients
were of Caucasian origin, whereas 75% of the patients
evaluated by Richey et al. were of African–American origin.
We found higher DBP in patients with CH than in patients
with EH, both at diagnosis and after 1 year of treatment. It
corresponds with findings in the Bogalusa Heart Study that
DBPinchildhood-predictedCHinadulthood[13]. This study
also confirmed the correlation between CH and DBP and
with impaired glucose tolerance.
There are no pediatric data concerning the risk
associated with the type of LV remodeling. Nonetheless,
Border et al. found diastolic dysfunction in as many as
36% of children with PH, and it mostly affected children
with CH [32]. Because LV remodeling depends on many
factors, including duration of hypertension, CH may also
d e v e l o pi no b e s ep a t i e n t s[ 33, 34]. This was shown by
Daniels et al., whoreportedthatdurationofhypertensionwas
significantly longer in children with CH in comparison with
patients with other patterns of LV remodeling [1].
Similar to other studies [35], we did not find any strong
relation between BP and LVMi. The relatively small impact
of BP on LV may be due to the relatively low absolute
values of blood pressure. As discussed previously, although
blood pressure values in children with PH are within the
hypertensive range in relation to age and growth, they are
relatively low in comparison with those found in secondary
hypertension or in hypertensive adults [16]. Second, the
range of absolute values of blood pressure observed in our
study was relatively narrow.
The TG/HDL ratio is a marker of metabolic abnormalities
typical for visceral obesity and hyperinsulinemia. These
abnormalities are also typical for adolescents with PH.
Hypertriglyceridemia with low HDL-cholesterol concentra-
tions indirectly points to insulin resistance [27]. However,
insulin resistance is linked to exposure to other growth
factors causing LVH [36]. We found that the main
determinants and correlates of RWT are the TG/HDL ratio,
WC, and oxidative stress. Although we did not find any
relation between insulin or HOMA-IR and RWT, patients
whose LV geometry did not normalize or who developed CH
had greater HbA1C and insulin concentrations during the
oral glucose tolerance test. Moreover, they increased insulin
secretion after the glucose load.
The third finding of our study is that in children with
PH, LVMi and LV geometry can normalize. Although
there is a small amount of data on the changes in LVMi
during treatment in children with PH, we did not find
any data on the changes in LV geometry. Although the
prevalence of NG increased and that of EH decreased
significantly, the prevalence of CH did not change.
Moreover, patients with CH did not experience lower
BP to the same extent as patients with EH. This suggests
t h a tC Hm i g h tb em o r ed i f f i c u l tt or e v e r s e .O n em a y
hypothesize that CH is a marker of advanced TOD, also
causing resistance to antihypertensive treatment. This
suggests that the assessment of LV geometry might be
valuable for the evaluation of further risk and may be an
indication for more intensive treatment.
One of the main limitations of our study is the relatively
low number of patients. The low absolute number of
patients with CH and CR limits the possibility of statistical
analysis. Second, because our patients were treated both
pharmacologically and with non-pharmacological meas-
ures, it is difficult to evaluate the effects of specific
treatments. Moreover, we did not monitor adherence to
non-pharmacological treatment including sodium intake
and physical activity. Similarly, although we treated
patients according to guidelines, we used different drugs
(ACEi or ARBs). Those limitations are why we could only
evaluate determinants of change in LV geometry, but not
the effects of specific drugs. Another limitation is the racial
and ethnic homogeneity of our patients. For this reason our
results cannot be extrapolated to other racial groups.
Gender distribution was similar to that of other studies
and is typical of PH in adolescence [1, 31]. However,
potential gender-related effects on the evolution of LV
geometry should be observed in a larger group of patients.
Pediatr Nephrol (2011) 26:2201–2209 2207Concluding, our results indicate that in Caucasian children
with PH, the most prevalent type of LVH is EH. The main
determinants of EH are visceral obesity, of CH-insulin
resistance. Antihypertensive treatment leads to significant
improvement and normalization of LV geometry. However,
patients with CH are less prone to normalized LV geometry
and may require more intensive treatment.
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